VICTOZA (liraglutide), antidiabetic

• VICTOZA now has Marketing Authorisation in the treatment of type 2 (adult-onset) diabetes for the achievement of glycaemic control combined with basal insulin, with or without an oral antidiabetic, when these, combined with diet and exercise, do not provide adequate glycaemic control.
• Its efficacy has been demonstrated in placebo controlled study in triple therapy with basal insulin and metformin.
• Its use combined with basal insulin and metformin is restricted to patients with type 2 diabetes inadequately controlled by the combination of these two medicinal products and who are intolerant to or have a contraindication to the use of a sulfonylurea, or in whom triple therapy with insulin/metformin/sulfonylurea has failed.

-